---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-041504"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T22:17:33.078843+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology appoints Caroline Germa as CMO; Sergio Santillana resigns

## Summary
- Sergio Santillana resigns as CMO effective Feb 29, 2024; will consult through Dec 31, 2024 at $500/hour.
- Caroline Germa, M.D., appointed CMO effective Feb 29, 2024; brings 25+ years pharma experience.
- Dr. Germa previously EVP & CMO at Transcenta, senior roles at AstraZeneca, BMS, Novartis.
- Focus on advancing IK-930 (Hippo pathway) and IK-595 (RAS/RAF mutant cancers) Phase I programs.
- Company on track for clinical update in second half of 2024.

## SEC filing metadata
- accession: 0001193125-24-041504
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312524041504/0001193125-24-041504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312524041504/d774502d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-041504
- JSON: https://secwatch.observer/filing/0001193125-24-041504.json
- Plain text: https://secwatch.observer/filing/0001193125-24-041504.txt

## Key facts
- Executive change
  Sergio Santillana resigned as Chief Medical Officer at ImageneBio, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On February 20, 2024, Sergio Santillana, M.D., M.Sc., MBA, notified Ikena Oncology, Inc. (the “Company”) of his decision to resign from his role at the Company as Chief Medical Officer effective as of February 29, 2024, with his last day of employment being March 5, 2024 (the “Departure Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312524041504/0001193125-24-041504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.